Literature DB >> 10528773

Antiperistaltic ileostomy using the long terminal ileal segment.

N G Oh1, I S Kang, G A Song, M S Sim.   

Abstract

PURPOSE: This study was undertaken to determine whether reversed terminal ileal segments can be used to decrease ileostomy output in patients who have undergone total proctocolectomy and ileostomy for ulcerative colitis or familial adenomatous polyposis.
METHODS: An approximately 25-cm length of terminal ileum was reversed in an antiperistaltic manner, and the new terminal ileal end was used for the ileostomy constructed in the usual manner. Six patients underwent this procedure and were compared with six patients who had conventional total proctocolectomy and ileostomy. Variables studied included weight of ileostomy output and the weight of the filtered fluid component. Data were obtained on seven different occasions during a two-month period beginning three months after the operation. Analysis was done using Student's t-test.
RESULTS: There was a statistically significant decrease in the weight of the average 24-hour ileostomy effluent in those patients undergoing reversed antiperistaltic loop procedures. There was also a statistically significant decrease in the filterable liquid proportions.
CONCLUSIONS: The antiperistaltic ileostomy is effective in reducing the daily amount of ileostomy effluent and facilitates stoma care, owing to its diminished liquid component.

Entities:  

Mesh:

Year:  1999        PMID: 10528773     DOI: 10.1007/bf02234224

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  2 in total

1.  Ileostomy diarrhea.

Authors:  Andrew W DuPont; Joseph H Sellin
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

2.  Anti-peristaltic ileocolonproctoplasty: a salvage procedure in extensive resective colorectal surgery.

Authors:  Vincenzo Violi; Renato Costi; Federico Marchesi; Stefano Cecchini; Leopoldo Sarli; Luigi Roncoroni
Journal:  Int J Colorectal Dis       Date:  2007-07-03       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.